The trial enrolled 91 participants with HER2-mutant NSCLC who had received prior anticancer treatments and showed that 55% of participants responded positively to T-DXd treatment, with a median duration of response lasting 9.3 months, emphasizing the importance of HER2 mutation testing in lung cancer patients to identify those who may benefit from this targeted therapy [6]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.